These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28444658)

  • 21. Revealing vilazodone's binding mechanism underlying its partial agonism to the 5-HT
    Zheng G; Xue W; Yang F; Zhang Y; Chen Y; Yao X; Zhu F
    Phys Chem Chem Phys; 2017 Nov; 19(42):28885-28896. PubMed ID: 29057413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-blind switch study of vilazodone in the treatment of major depressive disorder.
    Grant JE; Redden SA; Leppink EW
    Int Clin Psychopharmacol; 2017 May; 32(3):121-126. PubMed ID: 28177953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
    Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An 8-Week Randomized, Double-Blind Trial Comparing Efficacy, Safety, and Tolerability of 3 Vilazodone Dose-Initiation Strategies Following Switch From SSRIs and SNRIs in Major Depressive Disorder.
    Rele S; Millet R; Kim S; Paik JW; Kim S; Masand PS; Patkar AA
    Prim Care Companion CNS Disord; 2015; 17(4):. PubMed ID: 26693034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparative study of paroxetine and mianserin in depression in elderly patients: efficacy, tolerance, serotonin dependence].
    Daléry J; Aubin V
    Encephale; 2001; 27(1):71-81. PubMed ID: 11294041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D; Bridgman K; Buis C
    J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in immunomodulatory properties between venlafaxine and paroxetine in patients with major depressive disorder.
    Chen CY; Yeh YW; Kuo SC; Liang CS; Ho PS; Huang CC; Yen CH; Shyu JF; Lu RB; Huang SY
    Psychoneuroendocrinology; 2018 Jan; 87():108-118. PubMed ID: 29055264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vilazodone for the Treatment of Depression: An Update.
    Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Pae CU
    Chonnam Med J; 2016 May; 52(2):91-100. PubMed ID: 27231672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized controlled pilot trial of vilazodone for adult separation anxiety disorder.
    Schneier FR; Moskow DM; Choo TH; Galfalvy H; Campeas R; Sanchez-Lacay A
    Depress Anxiety; 2017 Dec; 34(12):1085-1095. PubMed ID: 29071764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone.
    Khan A; Durgam S; Tang X; Ruth A; Mathews M; Gommoll CP
    Prim Care Companion CNS Disord; 2016; 18(2):. PubMed ID: 27486544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled study.
    Clayton AH; Durgam S; Li D; Chen C; Chen L; Mathews M; Gommoll CP; Szegedi A
    Int Clin Psychopharmacol; 2017 Jan; 32(1):27-35. PubMed ID: 27643885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ACS chemical neuroscience molecule spotlight on viibryd (Vilazodone).
    Hopkins CR
    ACS Chem Neurosci; 2011 Oct; 2(10):554. PubMed ID: 22860155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measurement-Based Care Versus Standard Care for Major Depression: A Randomized Controlled Trial With Blind Raters.
    Guo T; Xiang YT; Xiao L; Hu CQ; Chiu HF; Ungvari GS; Correll CU; Lai KY; Feng L; Geng Y; Feng Y; Wang G
    Am J Psychiatry; 2015 Oct; 172(10):1004-13. PubMed ID: 26315978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 12-week prospective randomized controlled comparative trial of vilazodone and sertraline in Indian patients with depression.
    Bathla M; Anjum S
    Indian J Pharmacol; 2020; 52(1):10-15. PubMed ID: 32201441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological profiling of prospective antidepressant response in major depressive disorder: Associations with (neuro)inflammation, fatty acid metabolism, and amygdala-reactivity.
    Mocking RJT; Nap TS; Westerink AM; Assies J; Vaz FM; Koeter MWJ; Ruhé HG; Schene AH
    Psychoneuroendocrinology; 2017 May; 79():84-92. PubMed ID: 28262603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paroxetine versus placebo: a double-blind comparison in depressed patients.
    Claghorn JL; Kiev A; Rickels K; Smith WT; Dunbar GC
    J Clin Psychiatry; 1992 Dec; 53(12):434-8. PubMed ID: 1487471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression.
    de Paulis T
    IDrugs; 2007 Mar; 10(3):193-201. PubMed ID: 17351874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vilazodone, levomilnacipran and vortioxetine for major depressive disorder: the 15-min challenge to sort these agents out.
    Citrome L
    Int J Clin Pract; 2015 Feb; 69(2):151-5. PubMed ID: 25627335
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
    Wade AG; Schlaepfer TE; Andersen HF; Kilts CD
    J Psychiatr Res; 2009 Feb; 43(5):568-75. PubMed ID: 18954875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.